

CLAIMS

1. (2S)-2-Amino-2-cyclohexyl-1-((3RS)-3-fluoro-pyrrolidin-1-yl)-ethanone
or (S)-2-amino-2-cyclohexyl-1-(3,3-difluoro-pyrrolidin-1-yl)-ethanone, or a
5 pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising a therapeutically effective
amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof, and
a pharmaceutically acceptable diluent or carrier.
3. A pharmaceutical composition comprising
 - 10 a) a first compound comprising a compound of Claim 1, or a
pharmaceutically acceptable salt of said first compound; and
 - b) a second compound comprising insulin or an insulin analog;
insulinotropin; a biguanide; an α -2 antagonist or imidazoline; a glitazone; an aldose
reductase inhibitor; a glycogen phosphorylase inhibitor; a sorbitol dehydrogenase
15 inhibitor; a fatty acid oxidation inhibitor; an α -glucosidase inhibitor; a β -agonist; a
phosphodiesterase inhibitor; a lipid-lowering agent; an antiobesity agent; a vanadate,
vanadium complex or peroxovanadium complex; an amylin antagonist; a glucagon
antagonist; a growth hormone secretagogue; a gluconeogenesis inhibitor; a
somatostatin analog; an inhibitor of renal glucose; an antilipolytic agent; or a
20 pharmaceutically acceptable salt of said second compound.
4. A pharmaceutical composition of claim 3 further comprising a
pharmaceutically acceptable carrier or diluent.
5. A kit comprising:
 - 25 a) a first dosage form comprising a compound of Claim 1, or a
pharmaceutically acceptable salt thereof;
 - b) a second dosage form comprising insulin or an insulin analog;
insulinotropin; a biguanide; an α -2 antagonist or imidazoline; a glitazone; an aldose
reductase inhibitor; a glycogen phosphorylase inhibitor; a sorbitol dehydrogenase
inhibitor; a fatty acid oxidation inhibitor; an α -glucosidase inhibitor; a β -agonist; a
30 phosphodiesterase inhibitor; a lipid-lowering agent; an antiobesity agent; a vanadate,
vanadium complex or peroxovanadium complex; an amylin antagonist; a glucagon
antagonist; a growth hormone secretagogue; a gluconeogenesis inhibitor; a
somatostatin analog; an inhibitor of renal glucose; an antilipolytic agent; or a
pharmaceutically acceptable salt thereof; and

c) a container.

6. A method of inhibiting dipeptidyl peptidase-IV in a mammal comprising administering to said mammal in need of dipeptidyl peptidase inhibition a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.

7. A method of inhibiting dipeptidyl peptidase-IV in a mammal comprising administering to said mammal in need of dipeptidyl peptidase-IV inhibition a therapeutically effective amount of a pharmaceutical composition of any one of claims 2, 3 or 4.

8. A method of treating a condition mediated by dipeptidyl peptidase-IV inhibition in a mammal comprising administering to said mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.

9. A method of treating a condition mediated by dipeptidyl peptidase-IV inhibition in a mammal comprising administering to said mammal in need of such treatment a therapeutically effective amount of a pharmaceutical composition of any one of claims 2, 3 or 4.

10. A method of claim 8 wherein said condition treated is Type 2 diabetes, metabolic syndrome, hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, disease progression in Type 2 diabetes, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome or inflammatory bowel syndrome.

11. The method of claim 10 wherein the condition treated is Type 1 diabetes.

12. A prodrug of a compound of claim 1, or a pharmaceutically acceptable salt of said prodrug.